At #CTAD2025, Novo Nordisk shared new phase 3 results from Evoke/Evoke+ trials, offering important insights that underscore a critical shift toward the next era of drug development, which will target the underlying biology of this complex disease.

bit.ly/4iMH1WH

Topline results from the Evoke & Evoke+ Phase 3 trials show new insights despite missed endpoints. ADDF’s early support helps advance research, and the data will guide future combination therapy strategies for #Alzheimer’s. bit.ly/4rgojdS

Mark Roithmayr, ADDF CEO, shares his journey in #philanthropy, reflecting on the lessons, people, & moments that shaped his leadership and impact on Team Powdered Donut. Tune in for a conversation full of heart and purpose-driven leadership, driving real-world change. bit.ly/3M9s5FG

The ADDF is proud to partner with JPAD on a landmark issue on combination therapies. Just as they transformed cancer care, combination therapies are poised to do the same for #Alzheimer’s, providing a roadmap for advancing critical research.

bit.ly/3XqcdRA

The Annual Fall Symposium & Luncheon celebrated 27 years of vision from Leonard & Ronald Lauder, inspiring science & honorees! Phebe Farrow Port received the Charles Evans Award and Martha & Peter Webster received the Visionary Partner Award. bit.ly/47letQ0

The ADDF celebrates the opening of the Center for Aging Well at Yale Nursing, led by Dr. Miia Kivipelto. Her pioneering work in brain health and aging continues to shape the future of precision prevention and #Alzheimer’s care.
bit.ly/4hFhUVe

In a special Power of Ideas series, Howard Fillit highlighted the pivotal inflection point #Alzheimer’s science has reached in recent years. The ADDF is driving #breakthroughs through bold partnerships and cross-sector #collaboration. @milkeninstitute.org

milkeninstitute.org/content-hub/...

Today, our partners C2N Diagnostics submitted the #PrecivityAD2 blood test to the #FDA for approval, enabling earlier diagnosis and intervention for Alzheimer's treatment, a core tenet of the ADDF's DxA. The next frontier is precision medicine. bit.ly/46Lw4yV

The ADDF’s DxA announced two milestones: the release of #SpeechDx’s first data tranche & a new partnership with
Callyope. This gold-standard dataset will power a new generation of #AI tools to detect, diagnose, monitor, and even treat Alzheimer’s.

bit.ly/4ohctOz

The European Commission has authorized #Kisunla, marking a new era in #Alzheimer's treatment and accelerating global innovation. This milestone expands access for patients and families, enabling early detection and treatments that help slow decline. @elilillyandcompany.bsky.social
bit.ly/46mYY9M

Today marks a great step forward with the first-ever #FDA approval of the subcutaneous formulation of #Leqembi (lecanemab), a major advancement ushering in the next gen of #Alzheimer’s care with combination therapy and precision medicine.
bit.ly/47Pga8Y